Intended Use

“MagQu” Phospho-α-synuclein Control Solution is used as a standard control for “MagQu” Phospho-α-synuclein IMR Reagent (MF-PS1-0060).

Introduction

Parkinson’s disease (PD) is characterized by the intraneuronal α-synuclein inclusions called Lewy bodies. Increase of phosphorylation of α-synuclein in Serine 129 (p-ASC129) has been correlated with the aggregation, toxicity, protein interaction and turnover of α-synuclein. Thus, p-ASC129 can indicate the pathogenesis of PD.^1,2

Principle of Test

Phospho-α-synuclein Control Solution is used as a standard control for “MagQu” Phospho-α-synuclein IMR Reagent (MF-PS1-0060). The antibody conjugated on the surface of Fe₃O₄ magnetic particles (~ 50 nm) could bind with Phosphorylated α-synuclein and form clusters. With the increase of cluster, the signal of ac susceptibility ( χac ) will decrease in the applied ac magnetic field. That is the principle of Immuno Magnetic Reduction (IMR). By measuring the reduction of χac, we can quantify the Aβ1-42 protein in the sample easily and accurately.³

References

1. Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M., Siderowf, A. D., Hurtig, H., Litvan, I., Schiess, M. C., Peskind, E. R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein, D. S., Jensen, P. H., Yang, H., Cain, K. C., Zhang, J. (2012). Phosphorylated α-synuclein in Parkinson's disease. Science translational medicine, 4(121), 121ra20.
2. Oueslati A. (2016). Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?. Journal of Parkinson's disease, 6(1), 39-51. 
3. Che-Chuan Yang, Shieh-Yueh Yang, Jen-Jie Chieh, Herng-Er Horng, Chin-Yih Hong, Hong-Chang Yang, K. H. Chen, B. Y. Shih, Ta-Fu Chen, and Ming-Jang Chiu, “Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro”, ACS Chem. Neurosci. 2, 500 (2011).